Scientific Program
(as of May 2023)
Wednesday, May 31, 2023
17h00 – 18h00
General Assembly E-ISFA
(by invitation only)
Thursday, June 1, 2023
08h30 – 08h55
Opening Ceremony
Chairs: Bernd Hohenstein, ISFA President (DE), Wolfgang Ramlow, E-ISFA President (DE)
Congress Opening by
Bernd Hohenstein, ISFA President (DE)
Wolfgang Ramlow, E-ISFA President (DE)
Ulrich Julius, Honorary Congress President E-ISFA (DE)
Horst Klinkmann, Honorary Congress President ISFA (DE)
09h00 – 10h20
Apheresis around the world I:
Country specific aspects
Chairs:
Shamanna Iyengar (Bangalore, IN)
Olivier Moranne (Nimes, FR)
Kurt Derfler (Institute ATHOS, Vienna, AT)
Organization and national activities of therapeutic apheresis in Austria
Ken Yamaji (Juntendo University, Tokyo, JP)
Organization and national activities of therapeutic apheresis in Japan
Amber Sanchez (University of California San Diego, US)
Organization and national activities of therapeutic apheresis in the USA
Selected from abstracts:
Nosakhare G. Bazuaye et al. (Igbinedion University Teaching Hospital, Benin, Nigeria)
Apheresis activities in a low resource country Nigeria: a five years report of a single center
Lipid disorders and CVD I:
Lipid disorders – it all starts with the measurement
Chair:
Patrick Moriarty (Kansas City, US)
Jeffrey Kroon (Amsterdam, NL)
Patrick Moriarty (University of Kansas Medical Center, Kansas City, US)
Lipoprotein-apheresis and its effect on HDL functionality
Johanna Schachtl-Riess (Medical University of Innsbruck, AT)
Lipoprotein(a) – from genetics to phenotype
Jeffrey Kroon (University of Amsterdam, NL)
Evidence for a strong pro-inflammatory potential of lipoprotein(a)
Winfried März (SYNLAB Akademie, DE)
Dyslipidemia – it all starts with a correct measurement
10h20 – 10h45
Coffee Break, Exhibition & Poster Viewing
10h45 – 12h05
Apheresis around the world II:
South East Asian perspectives
Chairs:
Sasitorn Siritho (Bangkok, TH)
Wolfgang Ramlow (Rostock, DE)
Sasitorn Siritho (Bumrungrad International Hospital, TH)
Systematic review of TPE practices in central neuroimmunological disorders: evolving concepts in South East Asia
Lu Fiong Hiew (Kuala Lumpur Hospital, MY)
Uniting the world through TPE: SEATPEC challenges & potential future collaborations
Nghia Hoang (Military Hospital, Ho Chi Minh, VN)
TPE and its challenges in Vietnam
Dhayalen Krishnan (Kuala Lumpur General Hospital, MY)
Introduction to SEATPEC, best practices and TPE guidelines in South East Asia
Registries
Registries as research tools in apheresis
Chairs:
Ulrich Julius (Dresden, DE)
Volker Schettler (Goettingen, DE)
Christian Schumann (MVZ Kempten, DE)
CACOV – an apheresis registry for severely ill acute COVID patients
Bernd Hohenstein (Nephrologisches Zentrum Villingen-Schwenningen, DE)
The German Long-Covid Apheresis Register – design and first experiences
Wanja Bernhardt (Centre for Hypertension, Kidney and Metabolic diseases, Hanover, DE)
The German Lipoprotein Apheresis Register – a specific analysis of Lp(a) apheresis patients
Selected from abstracts:
Phandee Watanaboonyongcharoen et al. (Chulalongkorn University, Bangkok, TH)
A multicenter study of safety and incidence of adverse reactions associated with therapeutic apheresis in Thai patients
Apherese-Weiterbildung in deutscher Sprache:
Teil 1
Jens Ringel (Potsdam, DE)
Begrüßung
Uwe Wallstab (Wernigerode, DE)
Apherese ist nicht gleich Apherese
Reinhard Klingel (Köln, DE)
Apherese – mehr als nur Lipidreduktion
12h05 – 12h30
Coffee Break, Exhibition & Poster Viewing
12h30 – 13h45
13h45 – 14h00
Break
14h00 – 15h15
Apheresis around the world III:
Current updates & issues (from the American Society for Apheresis – ASFA)
Chairs:
Bernd Hohenstein (Villingen-Schwenningen, DE)
Joseph (Yossi) Schwartz (Tampa, US)
Joseph (Yossi) Schwartz (Moffit Cancer Center, Florida, US)
Growing variations in collections for further manufacturing
Betty Doggett (Carter BloodCare, Laird Hill, US)
Vascular access – issues & resolutions
Nicole Aqui (Perelman School of Medicine, University of Pennsylvania, US)
ASFA Guidelines for Therapeutic Apheresis – 2023
Autoimmune diseases I
Neuroimmune diseases and immunomodulation
Chairs:
Dhayalen Krishnan (Kuala Lumpur, MY)
Reinhard Klingel (Cologne, DE)
Wolfgang Köhler (Leipzig University, DE)
The role of apheresis therapy in MS and NMOSD
Olivier Moranne (CHU Caremeau Nimes, University Montpellier, FR)
Immunomodulatory effect associated with therapeutic plasmapheresis
Selected from abstracts:
Miriam Lanska et al. (University Hospital and Faculty of Medicine, Hradec Kralove, CZ)
Efficacy and safety of long-term immunoadsorption therapy in patients with myasthenia gravis
Selected from abstracts:
Virginia Athanasiadou et al. (National and Kapodistrial University of Athens, GR)
Therapeutic Plasmapheresis: A safe and effective periodic treatment for chronic inflammatory demyelinating polyneuropathy
Apherese-Weiterbildung in deutscher Sprache:
Teil 2
(14h00 – 15h30)
Jens Ringel (Potsdam, DE)
Ultima ratio bei Lipoproteinstörungen
Jens Ringel (Potsdam, DE)
Apherese, eine erfolgreiche Geschichte
Jörg Müller (Dresden, DE)
Heparin oder Citrat zur Antikoagulation
15h15 – 15h45
Coffee Break & Poster Viewing
15h45 – 17h30
Apheresis around the world IV
Apheresis therapy in Japan – JSFA Workshop
Chairs:
Ken Yamaji (Tokyo, JP)
Wolfgang Ramlow (Rostock, DE)
Ken Yamaj (Juntendo University, Tokyo, JP)
Updated Topics in PE, DFPP and plasma adsorption using the membrane separation
Shuzo Kobayashi (Shonan Kamakura General Hospital, Kanagawa, JP)
A novel LDL/fibrinogen apheresis ‘Rheocarna’ for patients with chronic limb-threatening ischemia
Tomoki Tanaka (Shiga University, Shiga, JP)
The development history of Toraymyxin and the update of clinical data of PMX-DHP
Makoto Naganuma (Kansai Medical University, Osaka, JP)
Developments and future perspective of apheresis therapy for inflammatory bowel disease
Apheresis in critical care medicine
Chairs:
Wladimir Szpirt (Copenhagen, DK)
Jan Kielstein (Braunschweig, DE)
Jan Stange (University Medical Center Rostock, DE)
Recent developments in the field of extracorporeal albumin detoxification (ECAD) for liver support
Gerd Klinkmann (University Medical Center Rostock, Department of Anesthesiology and Intensive Care Medicine, DE)
Extracorporeal immune cell therapy in sepsis
Steffen Mitzner (University Medical Center Rostock, DE)
Cytokine adsorption in sepsis and septic shock – still under debate
Amber Sanchez (University of California San Diego, US)
How to combine multiple extracorporeal systems in critical care
Sascha David (Zurich University Hospital, CH)
TPE in septic shock: to remove and replace
Apherese-Weiterbildung in deutscher Sprache:
Teil 3
(16h00 – 17h45)
Anja Ramlow (Potsdam, DE)
Pflegerische Aspekte in der Apheresebehandlung von
Long/Post-Covid Patienten
Volker Witt (Wien, AT)
Pflegerische Aspekte in der Apheresebehandlung von Kindern
Jens Ringel (Potsdam, DE)
Vorstellung der E-ISFA
Jens Ringel (Potsdam, DE)
Verabschiedung
17h30 – 19h30
Welcome Reception & Poster Session
Friday, June 2, 2023
08h30 – 09h50
Apheresis around the world V:
Country specific aspects
Chairs:
Amber Sanchez (San Diego, US)
Kurt Derfler (Vienna, AT)
Shamanna Iyengar (Manipal Academy of Higher Education, IN)
On the way to establish a lipid apheresis program in India by Lipid Association of India (LAI)
Ahmad AlSaraf (Sabah AlAhmad Cardiac Center, KW)
LDL apheresis in homozygous familial hypercholesterolemia in Kuwait
Luigi Vernaglione (Perrino Hospital, Brindisi, IT)
Cross sectional analysis of apheretical therapies in Italy
Olivier Moranne (CHU Caremeau Nimes, University Montpellier, FR)
Organization and national activities of therapeutic apheresis in France
Guest workshop:
Association of German Dialysis Centers (DN e. V.)
Chairs:
Georg Schlieper (Hanover, DE)
Wladimir Szpirt (Copenhagen, DK)
Georg Schlieper (Dialysis Centre Hanover, DE)
Is there a role for immunoadsorption in Post Covid?
Volker Schettler (Center of Nephrology, Dialysis and Apheresis, Göttingen, DE)
The German Lipoprotein Apheresis Registry (GLAR) – Summary of the tenth annual report
Jan Kielstein (Braunschweig Hospital, DE)
From sepsis to COVID – apheresis therapy in critical care medicine
09h00 – 12h00
Apherese-Weiterbildung in deutscher Sprache:
Jens Ringel (Potsdam, DE)
Schwester Anja Ramlow (Rostock, DE)
Begrüßung
Gruppenarbeit an den verschiedenen Maschinen mit Erfahrungsaustausch unter den Pflegenden zu je 150 min
(unter Beteiligung der Medizinprodukte-Hersteller)
09h50 – 10h20
Coffee Break, Exhibition & Poster Viewing
10h20 – 12h10
COVID-19 I:
Apheresis in COVID-19 and its complications
Chairs:
Julia Weinmann-Menke (Mainz, DE)
Bernd Hohenstein (Villingen-Schwenningen, DE)
Carmen Scheibenbogen (Charité – Universitätsmedizin Berlin, DE)
Long-term consequences of COVID and current therapeutic perspectives
Beate Jäger (Praxis Mühlheim a. d. R., DE)
Long COVID – why apheresis therapy could make the difference
Harald Matthes (Havelhöhe Community Hospital, Berlin, DE)
Is apheresis therapy an option for neuroinflammatory Post-vaccination syndrome?
Ulrich Paul Hinkel (Zentralklinik Bad Berka, DE)
Post-COVID-19 and post COVID-19-vaccination syndrome
Patient reported outcomes after DFPP, summary of 20 cases
Panel discussion – pro and contra
Lipid disorders and CVD II:
Apheresis targeting microcirculation and inflammation
Chairs:
Luigi Vernaglione (Brindisi, IT)
Wanja Bernhardt (Hanover, DE)
Luigi Vernaglione (Perrino Hospital, Brindisi, IT)
Apheresis to improve rheology – indications and results
Dusit Lumlertgul (Faculty of Medicine, Chiang Mai, TH)
Double filtration plasmapheresis (DFPP) to improve microcirculation
Jan Torzewski (Allgäu Hospital Network, Kempten, DE)
CRP – from laboratory parameter to key player of inflammation
Selected from abstracts:
Rosita Bihariesingh et al. (Academic Hospital Paramaribo Suriname)
First-in-Man: Plasmapheresis with a novel blood separation device in hypertriglyceridemia and acute pancreatitis
Selected from abstracts:
Mohamed Sedky et al. (Kuwait Central Blood Bank)
A fifteen-years analysis of therapeutic apheresis practices in state of Kuwait
Selected from abstracts:
Sergei Pokrovsky (National Medical Research Centre of Cardiology, Moscow, RU)
The contribution of Russian Scientists to the development of adsorption columns for therapeutic apheresis
12h10 – 12h30
Lunch Break, Exhibition & Poster Viewing
12h30 – 13h45
13h45 – 14h00
Lunch Break, Exhibition & Poster Viewing
14h00 – 15h20
COVID-19 II:
Treatment approaches in COVID and its consequences
Chairs:
Yoshihiro Endo (Otsu, Shiga, JP)
Steffen Mitzner (Rostock, DE)
Wladimir M. Szpirt (Rigshospitalet, Copenhagen, DK)
Plasma exchange utilizing convalescent plasma in severe COVID patients
Sebastian Koball (University Medical Center Rostock, DE)
How to evaluate apheresis efficacy in patients suffering from Long COVID?
Gunnar Bücker (Nephrology group practice, Osnabrück, DE)
First clinical results after HELP apheresis in Long COVID Syndrome
Julia Weinmann-Menke (Universitätsmedizin Mainz, DE)
Removal of circulating antibodies to adenoassociated virus vectors by immunoadsoption
New guidelines and developments:
Technical regulations and developments
Chairs:
Victoria Weber (Krems, AT)
Andre Kaplan (Plainvile, US)
Uwe H. Wallstab (mdXperts GmbH, Cologne, DE)
Relevance of sufficient clinical safety and performance data to maintain CE mark of apheresis devices
Viktoria Weber (Danube University Krems, AT)
Influence of the column surface on therapeutic apheresis – an old issue but new developments are rising
Selected from abstracts:
Andrew Aswani et al. (Santersus AG, CH)
Safety and performance of the NucleoCapture®Column for selective cfDNA/NETs apheresis in patients with sepsis
Selected from abstracts:
Kensuke Owari et al. (TAGCyx Biotechnologies, Inc., Tokyo, JP)
Development of next generation apheresis using artificial base DNA Aptamer
Lipid disorders and CVD III:
Workshop German Lipid League
Chairs:
Anja Vogt (Munich, DE)
Volker Schettler (Goettingen, DE)
Oliver Weingärtner (University Hospital Jena, DE)
A nationwide initiative to reach lipid targets
Anja Vogt (Ludwig Maximilians University Hospital, Munich, DE)
Novel lipid lowerting medications – current status and future perspectives
Ulrich Julius (University Hospital Dresden, DE)
Cardiovascular events before and during apheresis treatment – a detailed analysis for vascular regions
13h00 – 15h30
Apherese-Weiterbildung in deutscher Sprache:
Gruppenarbeit an den verschiedenen Maschinen mit Erfahrungsaustausch unter den Pflegenden zu je 150 min
(unter Beteiligung der Medizinprodukte-Hersteller)
Jens Ringel (Potsdam, DE) Verabschiedung
15h20 – 15h45
Coffee Break, Exhibition & Poster Viewing
15h45 – 17h30
Lipid disorders and CVD IV:
Treatment modalities in clinial practice
Chairs:
Mariko Harada-Shiba (Osaka, JP)
Tiziana Sampietro (Pisa, IT)
Wanja Bernhardt (Dialysis Centre Hanover, DE)
Long-term experience of Lp(a) apheresis in outpatient care
Tiziana Sampietro (National Research Council Institute of Clinical Physiology, Pisa, IT)
The role of lipoprotein apheresis on hypercholesterolemia and Lp(a) – the Pisa experience
Ulrich Julius (University Hospital Dresden, DE)
Comparison of the plasma lipoprotein apheresis systems MONET and Lipidfiltration from Diamed vs. the whole blood apheresis system DALI in the treatment of patients with cardiovascular disease and severe dyslipidemia
Jannecke Mulder (NL)
Quality of life in Dutch hoFH patients
Mariko Harada-Shiba (National Cerebral and Cardiovascular Center, Osaka, JP)
Development of novel drug for primary chylomicronemia by using antisense
Autoimmune diseases II:
Apheresis in rheumatologic and inflammatory bowel disease
Chairs:
Ken Yamaji (Tokyo, JP)
Harald Matthes (Berlin, DE)
Andreas Kronbichler (Medical University Innsbruck, AT)
Apheresis therapy in autoimmune vasculitides – PEXIVAS is not the end
Yoshihiro Endo (Shiga University of Medical Science, Otsu, JP)
Novel hemo-adsorbent for ulcerative colitis in Japan
Makoto Naganuma (Keio University School of Medicine, Tokyo, JP)
Recent trends of apheresis treatment for inflammatory bowel disease
Ken Yamaji (Juntendo University, Tokyo, JP)
Is apheresis therapy still an option in rheumatic diseases?
Selected from abstracts:
Natalia Jarzebska (University Hospital Dresden)
Apheresis treatment leads to increased levels of circulating neutrophil extracellular traps
Apheresis Service and Education
(in English language)
Chairs:
Betty Doggett (Laird Hill, US)
Rasheed Balogun (Charlottesville, US)
Christopher Dixon et al. (NHS Blood and Transplant, UK)
NHS Blood and Transplant – A Gold Standard Therapeutic Apheresis Service Model
Bridget Audsley et al. (NHS Blood and Transplant, NHS, Barnsley, UK)
Education and traininig in apheresis
Betty Doggett et al. (Carter BloodCare, Laird Hill, US)
Alliances and challenges of a community blood center mobile apheresis program providing care for donors and patients during COVID-19
Luigi Vernaglione et al. (Perrino Hospital, Brindisi, IT)
Effectiveness of therapeutic apheresis (TA): experience and outcomes analysis in an italian center
Rasheed Balogun (University of Virginia, Charlottesville, US)
Vascular access options for therapeutic apheresis
18h45 – 23h00
Congress Dinner
Saturday, June 3, 2023
08h30 – 10h15
Autoimmune diseases III
Apheresis for renal diseases
Chairs:
Andreas Kronbichler (Innsbruck, AT)
Wladimir Szpirt (Copenhagen, DK)
Lionel Rostaing (CHU Grenoble Alpes, Grenoble, FR)
Apheresis and desensitization before kidney transplantation
Benjamin Savenkoff (CHR Metz-Thionville, FR)
The role of apheresis therapy in glomerulopathies
Vladimir Kuklin (Bruggemann) (Ahus University Hospital, Lorenskog, NO)
Influence of therapeutic plasma exchange treatment on early survival of septic patients: a systematic review and meta-analysis
Wladimir Szpirt (Rigshospitalet, Copenhagen, DK)
An evolution in treatment of anti GBM nephritis – plasma exchange or imlifidase?
Selected from abstracts:
Haruna Yoshida et al. (Osaka City General Hospital)
Selective plasma exchange in critical care
Selected from abstracts:
Noemi Elisabeth Ginthör et al. (Medical University of Graz, AT)
Evaluation of iron deficiency and mechanisms of potential iron loss in patients undergoing immunoadsorption
Lipids and CVD V:
Pleiotropic and other expected windfall gains
Chairs:
Dursit Lumlertgul (Chiang Mai, TH)
N. N.
Grit Waitz (BioArtProducts, Rostock, DE)
Cardiometabolic risk assessment – the impact of comorbidities
Mariko Harada-Shiba (National Cerebral and Cardiovascular Center, Osaka, JP)
Lipoprotein apheresis for the treatment of familial hypercholesterolemia in Japan
Takafumi Ito (JP)
Efficacy and safety of LDL apheresis for the treatment of cholesterol crystal embolism
Selected from abstracts:
Lena Jochheim et al. (University Hospital Dresden, DE)
Actual situation at the Dresden Lipoprotein Apheresis Centre in 2023
Selected from abstracts:
Volker Schettler et al. (German Center for Neurodegenerative Diseases (DZNE) Goettingen, DE)
Effective exosomes reduction in hypercholesterinemic patients suffering from cardiovascular diseases by lipoprotein apheresis: exosomes pheresis
Selected from abstracts:
Romy Walther (University Hospital Dresden, DE)
Prognostic value of plasma lipidome for determining the risk of cardiovascular events in patients with lipoprotein apheresis
10h15 – 10h45
Coffee Break, Exhibition & Poster Viewing
10h45 – 12h30
Future perspectives of apheresis therapy
The future perspectives of apheresis
Chairs:
Bernd Hohenstein (Villingen-Schwenningen, DE)
Wolfgang Ramlow (Rostock, DE)
Patrick Moriarty (University of Kansas Medical Center, Kansas City, US)
Future perspectives in apheresis therapy – lipoprotein apheresis
Jan Kielstein (Braunschweig Hospital, DE)
Future perspectives in apheresis therapy – critical care medicine
Lionel Rostaing (CHU Grenoble Alpes, Grenoble, FR)
Future perspectives in apheresis therapy – renal diseases and transplantation
Reinhard Klingel (Apheresis Research Institute, Cologne, DE)
Future perspectives in apheresis therapy – immune-mediated conditions
Pediatric apheresis
Apheresis in children and adolescent patients
Chairs:
Julia Thumfart (Berlin, DE)
Volker Witt (Vienna, AT)
Wolfgang Ries (Diako Hospital Flensburg, DE)
Severe chronic fatigue syndrome (ME/CFS) in children – when is immunoadsorption justified?
Julia Thumfart (Charité – Universitätsmedizin Berlin, DE)
Apheresis therapy for pediatric neurological diseases – a German perspective
Volker Witt (Paediatric Hospital “St. Anna”, Vienna, AT)
ECP in children and young adults – special needs
Selected from abstracts:
Claudia Ootjers et al. (Leiden University Medical Centre)
Erythrocytapheresis prior to allogeneic stem cell transplantation in children with sickle cell disease is a safe and efficient method to lower sickle haemoglobin
Panel discussion:
Particularities in pediatric apheresis
12h30 – 13h00
Closing Ceremony & Awards Presentation
13h00
Farewell